National Institute on Minority Health and Health Disparities; Notice of Closed Meetings, 61611-61612 [2012-24869]
Download as PDF
rmajette on DSK2TPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 196 / Wednesday, October 10, 2012 / Notices
2010); however, current testing
procedures (16 CFR 1500.42) do not
provide criteria to classify results
obtained from a three-animal test.
NICEATM, in collaboration with
ICCVAM, conducted an analysis to
determine classification criteria based
on results from a three-animal test that
would maintain hazard classification
equivalent to that provided by current
testing procedures (16 CFR 1500.42).
The process for developing the
ICCVAM recommendations began with
a critical review of the analysis
(Haseman et al., 2011) and existing data
by the ICCVAM Interagency Ocular
Toxicity Working Group (OTWG). As
part of ICCVAM’s ongoing international
collaborations, scientists from the
European Union Reference Laboratory
for Alternatives to Animal Testing and
the Japanese Center for the Validation of
Alternative Methods served as liaisons
to the OTWG. The analysis (Haseman et
al., 2011) was provided to the Scientific
Advisory Committee on Alternative
Toxicological Methods (SACATM) at
the June 17–18, 2010 meeting (75 FR
26758, May 12, 2010) for comment. The
public was also given an opportunity to
comment at that meeting. The OTWG
then developed draft ICCVAM
recommendations regarding
classification criteria based on results
from a three-animal test that would
maintain hazard classification
equivalent to that provided by current
testing procedures (16 CFR 1500.42).
The draft ICCVAM recommendations
and supporting analysis (Haseman et al.,
2011) were made available on the
NICEATM–ICCVAM Web site (https://
iccvam.niehs.nih.gov/methods/ocutox/
reducenum.htm) for comment by the
broad stakeholder community (76 FR
50220, August 12, 2011).
ICCVAM considered the analysis
(Haseman et al., 2011), all public
comments, and the SACATM comments
in preparing the final ICCVAM test
method recommendations. The
recommendations are provided in the
ICCVAM Test Method Evaluation
Report: Identifying Chemical Eye
Hazards with Fewer Animals (NIH
Publication No. 12–7930), which is
available on the NICEATM–ICCVAM
Web site (https://iccvam.niehs.nih.gov/
methods/ocutox/reducenum-TMER.
htm). ICCVAM concludes that using a
classification criterion of one or more
positive animals in a three-animal test
to identify chemicals and products that
are eye hazards will maintain hazard
classification equivalent to that
provided by current testing procedures
(16 CFR 1500.42 [CPSC, 2010]), while
using up to 50% to 83% fewer animals.
ICCVAM, therefore, recommends
VerDate Mar<15>2010
15:15 Oct 09, 2012
Jkt 229001
consideration of this classification
together with eye safety testing
procedures that use a maximum of three
animals per test substance. Consistent
with ICCVAM’s duty to foster
interagency and international
harmonization (42 U.S.C. 285l-3), this
recommendation harmonizes the
number of animals used for eye safety
testing across U.S. regulatory agencies
and international test guidelines. The
ICCVAM TMER includes relevant ocular
toxicity regulations and guidelines,
applicable Federal Register notices,
public comments, and SACATM
meeting minutes.
Background Information on ICCVAM,
NICEATM, and SACATM
ICCVAM is an interagency committee
composed of representatives from 15
Federal regulatory and research agencies
that require, use, generate, or
disseminate toxicological and safety
testing information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability and promotes
the scientific validation and regulatory
acceptance of testing methods that more
accurately assess the safety and hazards
of chemicals and products and that
reduce, refine (enhance animal wellbeing and lessen or avoid pain and
distress), or replace animal use. The
ICCVAM Authorization Act of 2000 (42
U.S.C. 285l–3) established ICCVAM as a
permanent interagency committee of the
NIEHS under NICEATM. NICEATM
administers ICCVAM, provides
scientific and operational support for
ICCVAM-related activities, and
conducts independent validation
studies to assess the usefulness and
limitations of new, revised, and
alternative test methods and strategies.
NICEATM and ICCVAM welcome the
public nomination of new, revised, and
alternative test methods and strategies
for validation studies and technical
evaluations. Additional information
about NICEATM and ICCVAM can be
found on the NICEATM–ICCVAM Web
site (https://iccvam.niehs.nih.gov).
SACATM was established in response
to the ICCVAM Authorization Act
(Section 285l–3[d]) and is composed of
scientists from the public and private
sectors. SACATM advises ICCVAM,
NICEATM, and the Director of the
NIEHS and NTP regarding statutorily
mandated duties of ICCVAM and
activities of NICEATM. SACATM
provides advice on priorities and
activities related to the development,
validation, scientific review, regulatory
acceptance, implementation, and
national and international
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
61611
harmonization of new, revised, and
alternative toxicological test methods.
Additional information about SACATM,
including the charter, roster, and
records of past meetings, can be found
at https://ntp.niehs.nih.gov/go/167.
References
CPSC. 2010. Federal Hazardous
Substances Act Regulations. 16 CFR
1500. Available: https://www.gpo.gov/
fdsys/pkg/CFR-2011-title16-vol2/pdf/
CFR-2011-title16-vol2-chapII-subchapC.
pdf.
Haseman J.K., Allen D.G., Lipscomb
E.A., Truax J.F., Stokes WS. 2011. Using
fewer animals to identify chemical eye
hazards: revised criteria necessary to
maintain equivalent hazard
classification. Regul Toxicol Pharmacol
61: 98–104.
Dated: October 3, 2012.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2012–24868 Filed 10–9–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Minority Health
and Health Disparities; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Minority Health and Health Disparities
Special Emphasis Panel; NIMHD Social,
Behavioral, Health Services, and Policy
Research on Minority Health and Health
Disparities (R01).
Date: November 7–9, 2012.
Time: 8 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Rockville Hotel, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Maryline Laude-Sharp,
Ph.D., Scientific Review Officer, National
Institute on Minority Health and Health
E:\FR\FM\10OCN1.SGM
10OCN1
61612
Federal Register / Vol. 77, No. 196 / Wednesday, October 10, 2012 / Notices
Disparities, National Institutes of Health,
6707 Democracy Blvd., Suite 800, Bethesda,
MD 20892, (301) 451–9536,
mlaudesharp@mail.nih.gov.
Name of Committee: National Institute on
Minority Health and Health Disparities
Special Emphasis Panel; NIMHD Basic and
Applied Biomedical Research on Minority
Health and Health Disparities (R01).
Date: November 15–16, 2012.
Time: 8 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Rockville Hotel, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Maryline Laude-Sharp,
Ph.D., Scientific Review Officer, National
Institute on Minority Health, and Health
Disparities, National Institutes of Health,
6707 Democracy Blvd., Suite 800, Bethesda,
MD 20892, (301) 451–9536,
mlaudesharp@mail.nih.gov.
Dated: October 3, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–24869 Filed 10–9–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
rmajette on DSK2TPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Peer Review of R01 Grant
Applications.
Date: November 14–15, 2012.
Time: 8:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Room
3An18, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Margaret J. Weidman,
Ph.D., Scientific Review Officer, Office of
Scientific Review, National Institute of
General Medical Sciences, National Institutes
of Health, 45 Center Drive, Room 3An18B,
VerDate Mar<15>2010
15:15 Oct 09, 2012
Jkt 229001
Bethesda, MD 20892, 301–594–3663,
weidmanma@nigms.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: October 3, 2012.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: October 3, 2012.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–24871 Filed 10–9–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
[FR Doc. 2012–24870 Filed 10–9–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Initial Review
Group; Training and Workforce Development
Subcommittee—A.
Date: November 14, 2012.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott, 5520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Carole H. Latker, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3An.18, Bethesda, MD
20892, 301–594–2848,
latkerc@nigms.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
PO 00000
Frm 00044
Fmt 4703
Sfmt 9990
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; MBRS SCORE.
Date: November 13, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda,
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Robert Horowits, Ph.D.,
Scientific Review Officer, National Institute
of General Medical Sciences, National
Institutes of Health, 45 Center Drive, Room
3An.18, Bethesda, MD 20892–6200, 301–
594–6904, horowitr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: October 2, 2012.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–24872 Filed 10–9–12; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\10OCN1.SGM
10OCN1
Agencies
[Federal Register Volume 77, Number 196 (Wednesday, October 10, 2012)]
[Notices]
[Pages 61611-61612]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-24869]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Minority Health and Health Disparities;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Minority Health and
Health Disparities Special Emphasis Panel; NIMHD Social, Behavioral,
Health Services, and Policy Research on Minority Health and Health
Disparities (R01).
Date: November 7-9, 2012.
Time: 8 a.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Rockville Hotel, 1750 Rockville Pike, Rockville,
MD 20852.
Contact Person: Maryline Laude-Sharp, Ph.D., Scientific Review
Officer, National Institute on Minority Health and Health
[[Page 61612]]
Disparities, National Institutes of Health, 6707 Democracy Blvd.,
Suite 800, Bethesda, MD 20892, (301) 451-9536,
mlaudesharp@mail.nih.gov.
Name of Committee: National Institute on Minority Health and
Health Disparities Special Emphasis Panel; NIMHD Basic and Applied
Biomedical Research on Minority Health and Health Disparities (R01).
Date: November 15-16, 2012.
Time: 8 a.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Rockville Hotel, 1750 Rockville Pike, Rockville,
MD 20852.
Contact Person: Maryline Laude-Sharp, Ph.D., Scientific Review
Officer, National Institute on Minority Health, and Health
Disparities, National Institutes of Health, 6707 Democracy Blvd.,
Suite 800, Bethesda, MD 20892, (301) 451-9536,
mlaudesharp@mail.nih.gov.
Dated: October 3, 2012.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-24869 Filed 10-9-12; 8:45 am]
BILLING CODE 4140-01-P